Telavant
在场
Telavant 的所有者是 Sumitomo Chemical.
是其中之一......
Sumitomo Chemical 是一家在股票代码 4005 (JP) 下上市的公司。
Sumitomo Chemical 在 6 个国家有直接业务。Sumitomo Chemical 拥有 27家子公司，其中包括 Asahi Chemical、Covant Therapeutics 和 Datavant。
他们在：
高管
查看带有其 5 名主要高管的组织结构图
Telavant 搜索最多的简介
- Frank Torti, Chairman and Chief Executive Officer
- Bittoo Kanwar, Chief Medical Officer
- Amy Mahery, Chief Commercial Officer
创建提醒
跟踪 Telavant 的高管变动
生物技术
Sumitomo Chemical 拥有 2,332 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
- Hopo Therapeutics 刚刚宣布为 226 筹款数百万美元。 (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
Telavant 的最新新闻稿
- Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant | Roivant Sciences Ltd.
- Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Posi
- Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases | Roivant Sciences Ltd.
- Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period | Roivant Sciences Ltd.
- Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease | Roivant Sciences Ltd.
- News & Presentations | Telavant
- View more press releases Close
通过电子邮件
